First use of cenerimod for the treatment of systemic lupus erythematosus

A double-blind, randomised, placebo-controlled, proof-of-concept study of the selective S1P1 receptor modulator.
A double-blind, randomised, placebo-controlled, proof-of-concept study of the selective S1P1 receptor modulator.